Dr Amanda Hudson

Sydney Neuro-oncology Group Postdoctoral Fellow
Bill Walsh Translational Cancer Research Laboratory, Kolling Institute
Northern Sydney Local Health District
Sydney Medical School Northern
University of Sydney

Telephone +61 2 9926 4722
Fax +61 2 9926 4035

Map

Keywords

Immunotherapy; Mesothelioma; Brain tumours

Clinical Specialty

Oncology

Selected grants

2018

  • Combination therapy to combat cancer; McKelvey K, Howell V, Biggs M, Kamitakahara H, Colvin E, Hudson A; Mark Hughes Foundation (HMRI)/Hunter Medical Research Institute Fellowship.

2017

  • Investigating Inflammation and Coagulation in Brain Cancer; Howell V, Hudson A, Wheeler H, McKelvey K; Sydney Neuro-Oncology Group/Research Grant.

2015

  • Proteomic profiling of matched primary and recurrent IDH mutanted gliomas; Hudson A; University of Sydney/Kickstart Grants Program.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Rath, E., Cheng, Y., Pinese, M., Sarun, K., Hudson, A., Weir, C., Wang, Y., Hakansson, A., Howell, V., Liu, G., Reid, G., Church, W., et al (2018). BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. PloS One, 13(8), 1-32. [More Information]
  • Hudson, A., Parker, N., Khong, P., Parkinson, J., Dwight, T., Ikin, R., Zhu, Y., Chen, J., Wheeler, H., Howell, V. (2018). Glioblastoma recurrence correlates with increased APE1 and polarization toward an immuno-suppressive microenvironment. Frontiers in Oncology, 8(AUG), 1-10. [More Information]
  • Parker, N., Hudson, A., Khong, P., Parkinson, J., Dwight, T., Ikin, R., Zhu, Y., Cheng, Z., Vafaee, F., Chen, J., Wheeler, H., Howell, V. (2016). Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Scientific Reports, 6, 1-10. [More Information]
  • Hudson, A., Colvin, E. (2016). Transgenic mouse models of SV40-induced cancer. ILAR Journal, 57(1), 44-54. [More Information]
  • Davis, I., Long, A., Yip, S., Espinoza, D., Thompson, J., Kichenadasse, G., Harrision, M., Lowenthal, R., Pavlakis, N., Azad, A., Hudson, A., Stockler, M., Martin, A., et al (2015). EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma. Annals of Oncology, 26(6), 1118-1123. [More Information]
  • Weir, C., Hudson, A., Peters, L., Howell, V. (2015). Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model. Journal of Visualized Experiments, 104, 1-12. [More Information]
  • Ashton, A., Le, T., Gomez-Sanchez, C., Morel-Kopp, M., McWhitney, B., Hudson, A., Mihailidou, A. (2015). Role of Nongenomic Signaling Pathways Activated by Aldosterone During Cardiac Reperfusion Injury. Molecular Endocrinology, 29(8), 1144-1155. [More Information]
  • Hudson, A., Weir, C., Moon, E., Harvie, R., Klebe, S., Clarke, S., Pavlakis, N., Howell, V. (2014). Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Scientific Reports, 4, 1-11. [More Information]
  • Hayes, S., Hudson, A., Clarke, S., Molloy, M., Howell, V. (2014). From mice to men: GEMMs as trial patients for new NSCLC therapies. Seminars in Cell & Developmental Biology, 27, 118-127. [More Information]
  • Weir, C., Hudson, A., Moon, E., Ross, A., Alexander, M., Peters, L., Langova, V., Clarke, S., Pavlakis, N., Davey, R., Howell, V. (2014). Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunology Research, 2(5), 469-479. [More Information]
  • Colvin, E., Weir, C., Ikin, R., Hudson, A. (2014). SV40 TAg mouse models of cancer. Seminars in Cell & Developmental Biology, 27, 61-73. [More Information]

2018

  • Rath, E., Cheng, Y., Pinese, M., Sarun, K., Hudson, A., Weir, C., Wang, Y., Hakansson, A., Howell, V., Liu, G., Reid, G., Church, W., et al (2018). BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. PloS One, 13(8), 1-32. [More Information]
  • Hudson, A., Parker, N., Khong, P., Parkinson, J., Dwight, T., Ikin, R., Zhu, Y., Chen, J., Wheeler, H., Howell, V. (2018). Glioblastoma recurrence correlates with increased APE1 and polarization toward an immuno-suppressive microenvironment. Frontiers in Oncology, 8(AUG), 1-10. [More Information]

2016

  • Parker, N., Hudson, A., Khong, P., Parkinson, J., Dwight, T., Ikin, R., Zhu, Y., Cheng, Z., Vafaee, F., Chen, J., Wheeler, H., Howell, V. (2016). Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Scientific Reports, 6, 1-10. [More Information]
  • Hudson, A., Colvin, E. (2016). Transgenic mouse models of SV40-induced cancer. ILAR Journal, 57(1), 44-54. [More Information]

2015

  • Davis, I., Long, A., Yip, S., Espinoza, D., Thompson, J., Kichenadasse, G., Harrision, M., Lowenthal, R., Pavlakis, N., Azad, A., Hudson, A., Stockler, M., Martin, A., et al (2015). EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first line therapy for advanced renal cell carcinoma. Annals of Oncology, 26(6), 1118-1123. [More Information]
  • Weir, C., Hudson, A., Peters, L., Howell, V. (2015). Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model. Journal of Visualized Experiments, 104, 1-12. [More Information]
  • Ashton, A., Le, T., Gomez-Sanchez, C., Morel-Kopp, M., McWhitney, B., Hudson, A., Mihailidou, A. (2015). Role of Nongenomic Signaling Pathways Activated by Aldosterone During Cardiac Reperfusion Injury. Molecular Endocrinology, 29(8), 1144-1155. [More Information]

2014

  • Hudson, A., Weir, C., Moon, E., Harvie, R., Klebe, S., Clarke, S., Pavlakis, N., Howell, V. (2014). Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Scientific Reports, 4, 1-11. [More Information]
  • Hayes, S., Hudson, A., Clarke, S., Molloy, M., Howell, V. (2014). From mice to men: GEMMs as trial patients for new NSCLC therapies. Seminars in Cell & Developmental Biology, 27, 118-127. [More Information]
  • Weir, C., Hudson, A., Moon, E., Ross, A., Alexander, M., Peters, L., Langova, V., Clarke, S., Pavlakis, N., Davey, R., Howell, V. (2014). Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunology Research, 2(5), 469-479. [More Information]
  • Colvin, E., Weir, C., Ikin, R., Hudson, A. (2014). SV40 TAg mouse models of cancer. Seminars in Cell & Developmental Biology, 27, 61-73. [More Information]

To update your profile click here. For support on your academic profile contact .